Tessera Stock

www.tesseratherapeutics.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $558.91MM

Tessera Therapeutics is developing a genome engineering technology, Gene Writing™. The goal of Gene Writing™ is to be able to make genomic alterations that can be used to treat or cure disease. Tessera Therapeutics was founded in 2018 by Geoffrey von Maltzahn Ph.D., Jacob Rubens, Ph.D., and Noubar Afeyan, Ph.D. and is headquartered in Cambridge, MA.

Register for Details

For more details on financing and valuation for Tessera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Tessera.

Register Today

Team

Management Team

Hari Pujar Ph.D
Chief Operating Officer
Madhusudan Peshwa Ph.D
Chief Technology Officer, Cell Therapy
Michael Holmes Ph.D
Chief Scientific Officer
Iain McFadyen Ph.D
Chief Data Officer
Anne-Virginie Eggimann
Chief Regulatory Officer
Michael Severino MD
Chief Executive Officer & Board Member
Howard Liang Ph.D
Chief Financial Officer & President
David Davidson MD
Chief Medical and Development Officer

Other companies like Tessera in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Can “Gene Writing” Deliver What Gene Editing Can’t?
For the past few years, a biotech company called Tessera Therapeutics has been working away with a singular, lofty goal in mind: revolutionizing the technology used to edit DNA and RNA for scientific or therapeutic purposes.
Tessera CEO Interview
Tessera therapeutics has invented a tool for gene writing... Giving promise to entirely new disease therapies and prevention - at the genetic level.
Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech
Tessera Therapeutics, a company developing a genetic approach to treat and prevent diseases with backing from Flagship Pioneering, raised more than $300 million in its latest round.
Updated on: Sep 27, 2023